Jennison Associates LLC Invests $40.71 Million in Dianthus Therapeutics, Inc. $DNTH

Jennison Associates LLC acquired a new stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) during the first quarter, according to its most recent disclosure with the SEC. The fund acquired 485,136 shares of the company’s stock, valued at approximately $40,713,000.

Other hedge funds also recently made changes to their positions in the company. Wellington Management Group LLP increased its holdings in Dianthus Therapeutics by 3,366.9% in the 3rd quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock worth $101,431,000 after acquiring an additional 2,503,311 shares in the last quarter. Vestal Point Capital LP lifted its holdings in Dianthus Therapeutics by 88.2% during the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock valued at $59,616,000 after purchasing an additional 1,499,931 shares in the last quarter. State Street Corp boosted its position in shares of Dianthus Therapeutics by 124.7% in the fourth quarter. State Street Corp now owns 1,507,619 shares of the company’s stock worth $62,129,000 after purchasing an additional 836,571 shares during the period. Polar Capital Holdings Plc bought a new position in shares of Dianthus Therapeutics in the third quarter worth approximately $29,434,000. Finally, Marshall Wace LLP bought a new position in shares of Dianthus Therapeutics in the third quarter worth approximately $22,545,000. 47.53% of the stock is currently owned by institutional investors.

Dianthus Therapeutics Stock Performance

Shares of NASDAQ:DNTH opened at $101.00 on Tuesday. The firm has a fifty day moving average price of $89.24 and a 200 day moving average price of $74.40. Dianthus Therapeutics, Inc. has a fifty-two week low of $18.08 and a fifty-two week high of $107.99. The firm has a market cap of $5.52 billion, a price-to-earnings ratio of -24.46 and a beta of 1.20.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.22. The company had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.40 million. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. As a group, research analysts predict that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current year.

Insider Buying and Selling at Dianthus Therapeutics

In other Dianthus Therapeutics news, EVP Simrat Randhawa sold 26,530 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $90.62, for a total transaction of $2,404,148.60. Following the completion of the transaction, the executive vice president owned 4,000 shares of the company’s stock, valued at $362,480. This represents a 86.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Ryan Savitz sold 31,249 shares of the firm’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $101.03, for a total value of $3,157,086.47. Following the transaction, the executive vice president owned 31,249 shares of the company’s stock, valued at approximately $3,157,086.47. The trade was a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 87,779 shares of company stock valued at $7,985,235 in the last 90 days. Insiders own 3.02% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on DNTH. Wall Street Zen upgraded shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Friday. Wolfe Research reiterated an “outperform” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Guggenheim reissued a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Finally, Wedbush boosted their price objective on Dianthus Therapeutics from $103.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $117.82.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.